The Midwest Comparative Effectiveness Public Advisory Council, an independent Institute for Clinical and Economic Review (ICER) committee, during its September meeting found sufficient evidence for a net health benefit of treating nonmetastatic castration-resistant prostate cancer (nmCRPC) with either Astellas’ enzalutamide or Janssen’s apalutamide, but insufficient evidence of a net health benefit from Janssen’s abiraterone acetate.
ICER released its final evidence report and report-at-a-glance on the three antiandrogen therapies on Oct. 4.
The council, according to a press release, recommended “head-to-head” trials of the treatments. A majority of council members voted that “significant uncertainty remains regarding the long-term benefits of the treatments.”
“Reflecting the Council’s concerns, for this Final Report ICER conducted additional economic analyses showing that the long-term value for money of antiandrogen therapies is sensitive to the duration of treatment,” ICER CMO David Rind said in a statement. “Longer term data on duration of treatment and overall survival should further clarify the cost-effectiveness of these therapies.”
To read the final report, click here.